Literature DB >> 29146521

HLA-DQ-Gluten Tetramer Blood Test Accurately Identifies Patients With and Without Celiac Disease in Absence of Gluten Consumption.

Vikas K Sarna1, Knut E A Lundin2, Lars Mørkrid3, Shuo-Wang Qiao4, Ludvig M Sollid4, Asbjørn Christophersen5.   

Abstract

BACKGROUND & AIMS: Celiac disease is characterized by HLA-DQ2/8-restricted responses of CD4+ T cells to cereal gluten proteins. A diagnosis of celiac disease based on serologic and histologic evidence requires patients to be on gluten-containing diets. The growing number of individuals adhering to a gluten-free diet (GFD) without exclusion of celiac disease complicates its detection. HLA-DQ-gluten tetramers can be used to detect gluten-specific T cells in blood of patients with celiac disease, even if they are on a GFD. We investigated whether an HLA-DQ-gluten tetramer-based assay accurately identifies patients with celiac disease.
METHODS: We produced HLA-DQ-gluten tetramers and added them to peripheral blood mononuclear cells isolated from 143 HLA-DQ2.5+ subjects (62 subjects with celiac disease on a GFD, 19 subjects without celiac disease on a GFD [due to self-reported gluten sensitivity], 10 subjects with celiac disease on a gluten-containing diet, and 52 presumed healthy individuals [controls]). T cells that bound HLA-DQ-gluten tetramers were quantified by flow cytometry. Laboratory tests and flow cytometry gating analyses were performed by researchers blinded to sample type, except for samples from subjects with celiac disease on a gluten-containing diet. Test precision analyses were performed using samples from 10 subjects.
RESULTS: For the HLA-DQ-gluten tetramer-based assay, we combined flow-cytometry variables in a multiple regression model that identified individuals with celiac disease on a GFD with an area under the receiver operating characteristic curve value of 0.96 (95% confidence interval [CI] 0.89-1.00) vs subjects without celiac disease on a GFD. The assay detected individuals with celiac disease on a gluten-containing diet vs controls with an area under the receiver operating characteristic curve value of 0.95 (95% CI 0.90-1.00). Optimized cutoff values identified subjects with celiac disease on a GFD with 97% sensitivity (95% CI 0.92-1.00) and 95% specificity (95% CI 0.84-1.00) vs subjects without celiac disease on a GFD. The values identified subjects with celiac disease on a gluten-containing diet with 100% sensitivity (95% CI 1.00-1.00]) and 90% specificity (95% CI 0.83-0.98) vs controls. In an analysis of 4 controls with positive results from the HLA-DQ-gluten tetramer test, 2 had unrecognized celiac disease and the remaining 2 had T cells that proliferated in response to gluten antigen in vitro.
CONCLUSIONS: An HLA-DQ-gluten tetramer-based assays that detects gluten-reactive T cells identifies patients with and without celiac disease with a high level of accuracy, regardless of whether the individuals are on a GFD. This test would allow individuals with suspected celiac disease to avoid gluten challenge and duodenal biopsy, but requires validation in a larger study. Clinicaltrials.gov no: NCT02442219.
Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD38; Gluten-Sensitive; Gut-Homing; Noninvasive Test

Mesh:

Substances:

Year:  2017        PMID: 29146521     DOI: 10.1053/j.gastro.2017.11.006

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  20 in total

1.  Discriminative T-cell receptor recognition of highly homologous HLA-DQ2-bound gluten epitopes.

Authors:  Shiva Dahal-Koirala; Laura Ciacchi; Jan Petersen; Louise Fremgaard Risnes; Ralf Stefan Neumann; Asbjørn Christophersen; Knut E A Lundin; Hugh H Reid; Shuo-Wang Qiao; Jamie Rossjohn; Ludvig M Sollid
Journal:  J Biol Chem       Date:  2018-11-19       Impact factor: 5.157

Review 2.  Celiac Disease Revisited.

Authors:  João Calado; Mariana Verdelho Machado
Journal:  GE Port J Gastroenterol       Date:  2021-03-17

Review 3.  Review on pediatric coeliac disease from a clinical perspective.

Authors:  Margreet Wessels; Renata Auricchio; Jernej Dolinsek; Ester Donat; Peter Gillett; Karl Mårild; Caroline Meijer; Alina Popp; M Luisa Mearin
Journal:  Eur J Pediatr       Date:  2022-01-15       Impact factor: 3.183

Review 4.  Single-cell approaches to dissect adaptive immune responses involved in autoimmunity: the case of celiac disease.

Authors:  Ida Lindeman; Ludvig M Sollid
Journal:  Mucosal Immunol       Date:  2021-09-16       Impact factor: 7.313

Review 5.  Emerging Biomarkers for Screening and Management of Celiac Disease.

Authors:  Bilal Ahmad Mir; Tahir Majeed; Alka Singh; Mahendra Singh Rajput; Asheesh Kumar; Ashish Chauhan
Journal:  Biomed Res Int       Date:  2022-05-28       Impact factor: 3.246

Review 6.  Diagnosis of Celiac Disease: Taking a Bite Out of the Controversy.

Authors:  Justine M Turner
Journal:  Dig Dis Sci       Date:  2018-06       Impact factor: 3.199

7.  CD38 expression on gluten-specific T cells is a robust marker of gluten re-exposure in coeliac disease.

Authors:  Stephanie Zühlke; Louise Fremgaard Risnes; Shiva Dahal-Koirala; Asbjørn Christophersen; Ludvig M Sollid; Knut Ea Lundin
Journal:  United European Gastroenterol J       Date:  2019-09-07       Impact factor: 4.623

8.  Serum cytokines elevated during gluten-mediated cytokine release in coeliac disease.

Authors:  G Goel; A J M Daveson; C E Hooi; J A Tye-Din; S Wang; E Szymczak; L J Williams; J L Dzuris; K M Neff; K E Truitt; R P Anderson
Journal:  Clin Exp Immunol       Date:  2019-10-01       Impact factor: 4.330

9.  Whole blood interleukin-2 release test to detect and characterize rare circulating gluten-specific T cell responses in coeliac disease.

Authors:  R P Anderson; G Goel; M Y Hardy; A K Russell; S Wang; E Szymczak; R Zhang; K E Goldstein; K Neff; K E Truitt; L J Williams; J L Dzuris; J A Tye-Din
Journal:  Clin Exp Immunol       Date:  2021-02-28       Impact factor: 5.732

10.  A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease.

Authors:  Melinda Y Hardy; Gautam Goel; Amy K Russell; Swee Lin G Chen Yi Mei; Gregor J E Brown; Suyue Wang; Evan Szymczak; Ruan Zhang; Kaela E Goldstein; Kristin M Neff; Leslie J Williams; Kenneth E Truitt; John L Dzuris; Jason A Tye-Din; Robert P Anderson
Journal:  Front Immunol       Date:  2021-05-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.